Disclaimer

YOU ARE ABOUT TO ENTER AN ABBOTT COUNTRY OR REGION SPECIFIC WEBSITE.

Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions



DO YOU WISH TO CONTINUE AND ENTER THIS WEBSITE?

SJM-CV WEB-0718-0009

/content/bss/divisionalsites/livesites/reusable/cv-livesite/us/en/pages/home
30
CARDIOVASCULAR
hamburger
BACK
Technology

Technology Overview

Enhanced Detection and Treatment

Experience increased detection capabilities in traditionally challenging arrhythmias with Abbott’s new discriminator, VF Therapy Assurance.


Decrease time to treatment for arrhythmias in patients likely to be hemodynamically unstable


>800 patients annually with challenging arrhythmias could have their lives saved because of VF Therapy Assurance1

Safer Management of Care

Manage high DFTs with the industry’s most flexible option, DeFT Response™ technology. The programming options are designed to optimize rescue therapy to meet each patient’s unique physiology and changing needs.


Customized matching of shock waveform to patients’ cellular response time to lower DFTs

100% success in preserving a 10J safety margin with DeFT Response technology vs. 83% achievement of 10J safety margin in fixed-tilt group of patients with competitive devices2

Reduced Inappropriate Therapy

ShockGuard™ technology with DecisionTx™ programming is designed to reduce inappropriate therapy and minimize the need for programming adjustments at implant.

98.4% of patients did not receive inappropriate shocks at 1 year (CI: 97.2 -99.2, p<0.0001)3

This device is commercially available for use in select international markets.

References

  1. Data on file. 60101422 Internal Validation Report. Total 2019 global high-voltage implants, all manufacturers, estimated to be 440,434 units (Source: Abbott Market Research).
  2. Gabriels J, Budzikowski AS, Kassotis JT. Defibrillation waveform duration adjustment increases the proportion of acceptable defibrillation thresholds in patients implanted with single-coil defibrillation leads. Cardiology. 2013;124(2):71-75.
  3. Veltmann C, Wöhrle A, Busch M, et al. Reduction of inappropriate shocks of ICDs with enhanced SVT discriminators. EUROPACE presentation; 2017.
Indications, Safety & Warnings

MAT-2008635 v1.0

DO YOU WISH TO CONTINUE AND EXIT CARDIOVASCULAR.ABBOTT?

CONTENTS OF THE SITE ARE NOT UNDER THE CONTROL OF ABBOTT.

False
accessibility
© 2021 Abbott. All Rights Reserved. Please read the Legal Notice for further details.

Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.

YESNO
accessibility

DO YOU WISH TO CONTINUE AND EXIT CARDIOVASCULAR.ABBOTT?

CONTENTS OF THE SITE ARE NOT UNDER THE CONTROL OF ABBOTT.

YESNO
accessibility
© 2021 Abbott. All Rights Reserved. Please read the Legal Notice for further details.

Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.

YESNO
accessibility

The following content is intended for Healthcare Professionals except for those in France. Some of the content is not in compliance with the French Advertising law N°2011-2012 dated 29th December 2011, article 34.



Si vous êtes un professionnel de santé exerçant en France ou dans les territoires Français, veuillez visiter notre site en français.



Do you want to continue? 

YesNo